Observational studyBMC medicine2026
Evaluating DNA methylation markers and extended HPV genotyping in first-void urine for detecting high-grade cervical lesions in HPV-positive women: a cross-sectional study.
Observational study in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05065853 (Urinary and Vaginal HPV Testing as a Novel Cervical Cancer Screening Tool), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Urinary and Vaginal HPV Testing as a Novel Cervical Cancer Screening Tool: a Diagnostic Test Accuracy Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundFirst-void urine (FVU) collection for high-risk human papillomavirus (HPV) testing may reach un(der)-screened women in cervical cancer screening programs. This cross-sectional study investigated the clinical performance of DNA methylation markers ASCL1 and LHX8 in HPV-positive FVU for detecting high-grade cervical intraepithelial neoplasia and cancer (CIN2+ and CIN3+). Additionally, results were compared with paired HPV-positive clinician-collected cervical samples (CS) and HPV genotyping.
methodsPaired FVU and CS samples were collected from 286 women aged 23-64 years referred for colposcopy or cervical excision. Histological endpoints included 123 ≤ CIN1 (no dysplasia and CIN1), 38 CIN2, and 123 CIN3/AIS and 2 cancers. Samples were tested for HPV DNA and ASCL1/LHX8 methylation. Methylation test performance was evaluated by area under the curve (AUC) and logistic regression. Differences between paired samples and across methylation, HPV16/18, and extended HPV16/18/31/33/52 genotyping in FVU were tested using McNemar's test.
resultsASCL1 and LHX8 methylation levels in HPV-positive FVU increased significantly with disease severity. Methylation testing in FVU yielded an AUC of 0.76 (95% CI: 0.70-0.82) for CIN3 + and 0.73 (95% CI: 0.67-0.79) for CIN2 + , with sensitivities of 79.2% (95% CI: 71.0-85.9%) and 75.5% (95% CI: 68.1-81.9%), respectively, and a specificity of 57.0% (95% CI: 47.8-65.8%) for ≤ CIN1. In CS, methylation testing yielded higher AUCs of 0.84 (95% CI: 0.79-0.89) for CIN3 + and 0.80 (95% CI: 0.75-0.85) for CIN2 + , with significantly higher sensitivities (p ≤ 0.02) but lower specificity (p = 0.04) than FVU. In women aged ≥ 30 years, CIN3 + sensitivity and specificity for ≤ CIN1 were similar between FVU and CS (both p = 0.09). No significant differences in accuracy were observed between methylation testing and extended genotyping (p ≥ 0.35) in FVU, while methylation testing showed higher sensitivity (p < 0.01) but lower specificity (p < 0.01) than HPV16/18 genotyping.
conclusionsASCL1/LHX8 methylation testing in HPV-positive FVU showed promise for detecting high-grade cervical disease. Its performance in FVU did not differ significantly from extended HPV genotyping and, in women aged ≥ 30 years, was comparable to performance in CS. This supports methylation testing as a complementary triage test alongside HPV genotyping in urine-based cervical cancer screening, removing the need for follow-up cervical sampling. Further validation in HPV-positive FVU from un(der)-screened populations is warranted.
trial registrationClinicalTrials.gov: NCT05065853.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.